{"id":25410,"date":"2023-10-27T18:47:36","date_gmt":"2023-10-27T13:17:36","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=25410"},"modified":"2024-01-05T10:59:01","modified_gmt":"2024-01-05T05:29:01","slug":"aav-gene-therapies-for-hemophilia-b-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment","title":{"rendered":"AAV Gene Therapies for Hemophilia B Treatment: The Road to a Cure"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d57025791b9\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d57025791b9\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment\/#HEMGENIX_The_Only_Approved_Gene_Therapy_for_Hemophilia_B_Treatment\" >HEMGENIX: The Only Approved Gene Therapy for Hemophilia B Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment\/#Promising_Gene_Therapies_in_Pipeline_for_Hemophilia_B_Treatment\" >Promising Gene Therapies in Pipeline for Hemophilia B Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment\/#Challenges_with_Gene_Therapies_for_Hemophilia_B_Treatment\" >Challenges with Gene Therapies for Hemophilia B Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment\/#The_Bright_Future_of_Gene_Therapies_for_Hemophilia_B_Treatment\" >The Bright Future of Gene Therapies for Hemophilia B Treatment<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient levels of a blood protein called factor IX. Around <strong>3 in 100 individuals<\/strong> with hemophilia B produce an antibody to the factor IX replacement therapy used to treat or avoid their bleeding episodes, called an inhibitor. The inhibitor prevents the therapy from working, which makes it harder to avoid an episode of bleeding.&nbsp;<\/p>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>As per DelveInsight\u2019s analysis, in 2022, the <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-epidemiology-forecast\"><em>total treated prevalent population of hemophilia B<\/em><\/a><em> in the US was approximately <\/em><strong><em>4K<\/em><\/strong><em>. As per the estimates it can be observed that moderate hemophilia B cases are higher in number than mild and severe cases in the US.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Hemophilia B is a life-long condition. Currently, there is no cure, but researchers are actively engaged in finding the cure through gene therapy. One hope is that by inserting a healthy version of the defective blood factor gene, a person with hemophilia will be able to produce reasonable amounts of a factor on their own.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/infographics\/hemophilia-b-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161727\/Hemophilia-B-infographic-1024x194.webp\" alt=\"Hemophilia B infographic\" class=\"wp-image-25415\" width=\"768\" height=\"146\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161727\/Hemophilia-B-infographic-1024x194.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161727\/Hemophilia-B-infographic-300x57.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161727\/Hemophilia-B-infographic-150x28.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161727\/Hemophilia-B-infographic-768x145.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161727\/Hemophilia-B-infographic-1536x291.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161727\/Hemophilia-B-infographic-1568x297.webp 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161727\/Hemophilia-B-infographic.webp 1584w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/a><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-hemgenix-the-only-approved-gene-therapy-for-hemophilia-b-treatment\"><span class=\"ez-toc-section\" id=\"HEMGENIX_The_Only_Approved_Gene_Therapy_for_Hemophilia_B_Treatment\"><\/span><strong>HEMGENIX: The Only Approved Gene Therapy for Hemophilia B Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Gene therapy offers an exciting avenue for achieving a long-lasting cure in a single treatment for X-linked bleeding condition hemophilia, as opposed to the various ongoing clinical treatments. Patient data corroborates the potential for sustained, natural clotting factor production through gene therapy, eliminating the need for frequent injections of coagulation factors or alternative drugs. This has the potential to significantly reduce the overall cost of care. Hemophilia B stands out as an ideal candidate for gene therapy due to its varying factor level sensitivity to bleeding symptoms and the non-essential need for precise control. Moreover, only a fraction of hepatocytes need correction to effectively address the bleeding diathesis, as clotting factor proteins are secreted into the bloodstream.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26163212\/Hemgenix-Development-Timeline-in-the-US.webp\" alt=\"Hemgenix Development Timeline in the US\" class=\"wp-image-25417\" width=\"714\" height=\"192\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26163212\/Hemgenix-Development-Timeline-in-the-US.webp 952w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26163212\/Hemgenix-Development-Timeline-in-the-US-300x81.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26163212\/Hemgenix-Development-Timeline-in-the-US-150x40.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26163212\/Hemgenix-Development-Timeline-in-the-US-768x207.webp 768w\" sizes=\"(max-width: 714px) 100vw, 714px\" \/><\/figure>\n\n\n\n<p>In a milestone achievement, <strong>HEMGENIX (CSL Behring\/uniQure)<\/strong>, the groundbreaking gene therapy approved in 2022, has received the green light for <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-market\">treating adults grappling with hemophilia B<\/a>, a genetic disorder marked by a shortage of Factor IX. Designed for those who currently rely on Factor IX prophylaxis, have survived life-threatening hemorrhages, or frequently experience severe spontaneous bleeding incidents, HEMGENIX exhibited remarkable results in the Phase III clinical trial known as <strong>HOPE-B<\/strong>. This cutting-edge therapy demonstrated an impressive 64% reduction in all bleeding incidents and an astounding 77% decrease in bleeding episodes necessitating Factor IX treatment over a span of seven to eighteen months. Remarkably, the price tag for HEMGENIX is a staggering <strong>USD 3.5 million per dose<\/strong>, solidifying its status as the world\u2019s most expensive medication and a groundbreaking milestone as the first gene therapy approved for this rare disease.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-promising-gene-therapies-in-pipeline-for-hemophilia-b-treatment\"><span class=\"ez-toc-section\" id=\"Promising_Gene_Therapies_in_Pipeline_for_Hemophilia_B_Treatment\"><\/span><strong>Promising Gene Therapies in Pipeline for Hemophilia B Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The landscape of the <a href=\"https:\/\/www.delveinsight.com\/blog\/hemophilia-b-market\">hemophilia B treatment market<\/a> is poised to undergo significant changes in the near future due to the increasing global healthcare expenditure. Leading pharmaceutical companies such as <strong>Pfizer\/Spark Therapeutics (SPK-9001), Takeda (AskBio009)<\/strong>, and others are dedicated to advancing new therapies for hemophilia B, aiming to enhance symptom management and ultimately elevate the quality of life for patients.<\/p>\n\n\n\n<p><strong>Fidanacogene elaparvovec, previously SPK-9001 or PF-06838435<\/strong> is a novel, investigational bio-engineered AAV vector by <strong>Pfizer\/Spark Therapeutics<\/strong> which utilizes a high-activity F9 transgene for hemophilia B or factor IX deficiency. Currently, SPK-9001 is under Phase III (NCT03861273) clinical trial study. In September 2015, SPK-9001 received an <strong>orphan drug designation<\/strong> from the US FDA, and later in July 2016, it received <strong>breakthrough therapy designation<\/strong> from the FDA and PRIME from the EU. Pfizer recently announced that the US FDA has accepted a BLA for fidanacogene elaparvovec to treat adults with hemophilia B. The EMA has also accepted a marketing authorization application currently under review. This submission was based on the findings from the ongoing <strong>Phase III BENEGENE-2<\/strong> study (NCT03861273). It enrolled 45 participants who had completed at least six months of routine factor IX (FIX) prophylaxis therapy in the lead-in study (NCT03587116) and received a dose of fidanacogene elaparvovec.<\/p>\n\n\n\n<p><strong>AskBio009\/BAX 335<\/strong> is another <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight\">gene therapy in the early stage of development for hemophilia B treatment<\/a>. BAX 335 is an adeno-associated virus serotype 8 (AAV8)-based clotting factor IX (FIX) Padua (R338L) gene therapy for the treatment of hemophilia B. Takeda is currently conducting <strong>Phase I\/II trial<\/strong> for AskBio009. As per Phase I\/II results, no serious adverse event occurred. No clinical thrombosis, inhibitors, or other FIX Padua-directed immunity was reported. FIX expression was measurable in 7 of 8 participants; peak FIX activity displayed dose dependence (32.0% to 58.5% in cohort 3).<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"255\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161807\/Emerging-Gene-Therapies-for-Hemophilia-B-1024x255.webp\" alt=\"Emerging Gene Therapies for Hemophilia B\" class=\"wp-image-25416\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161807\/Emerging-Gene-Therapies-for-Hemophilia-B-1024x255.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161807\/Emerging-Gene-Therapies-for-Hemophilia-B-300x75.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161807\/Emerging-Gene-Therapies-for-Hemophilia-B-150x37.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161807\/Emerging-Gene-Therapies-for-Hemophilia-B-768x192.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161807\/Emerging-Gene-Therapies-for-Hemophilia-B.webp 1283w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Many <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight\">gene therapies for hemophilia B treatment<\/a> have been stopped in their development stages, such as <strong>Verbrinacogene setparvovec (FLT 180a) (Freeline Therapeutics) and SB-FIX (Sangamo Therapeutics)<\/strong>. The field of gene therapy for hemophilia B treatment has a low success rate and few key players. Most of the key players are developing their gene therapies outside the 7MM, mainly in China.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-challenges-with-gene-therapies-for-hemophilia-b-treatment\"><span class=\"ez-toc-section\" id=\"Challenges_with_Gene_Therapies_for_Hemophilia_B_Treatment\"><\/span><strong>Challenges with Gene Therapies for Hemophilia B Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Despite the widespread availability of safe and effective replacement therapy, <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-epidemiology-forecast\">patients with hemophilia B<\/a> continue to bear a substantial treatment burden, including issues like breakthrough bleeding, progressive joint disease, and the development of inhibitors. This unmet need is particularly pressing, given that hemophilia B affects approximately 3 in 100 people with hemophilia B, leading to increased treatment costs and greater risks to patient well-being. The emergence of inhibitors further compounds the problem by reducing the efficacy of factor IX in blood coagulation, negatively impacting patients\u2019 health, quality of life, and significantly driving up the overall cost of hemophilia B treatment.<\/p>\n\n\n\n<p>Moreover, the diagnosis of hemophilia B often faces delays, primarily due to factors like a clinical presentation that mirrors other hemorrhagic disorders and the delayed onset of symptoms. The predominant treatment options typically involve intravenous administration. Many patients, particularly children, express discomfort and inconvenience with this method. Treating hemophilia B comes at a considerable cost, and future treatment options, such as <a href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-to-treat-complex-diseases\">gene therapies<\/a> and extended half-life products, are also anticipated to be on the expensive side. Health authorities are likely to implement measures to control the pricing and utilization of these high-cost therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-the-bright-future-of-gene-therapies-for-hemophilia-b-treatment\"><span class=\"ez-toc-section\" id=\"The_Bright_Future_of_Gene_Therapies_for_Hemophilia_B_Treatment\"><\/span><strong>The Bright Future of Gene Therapies for Hemophilia B Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Currently, non-inhibitor drug candidates are the driving force behind hemophilia B treatment. The emergence of promising new contenders represents a notable disruption to the hemophilia B pharmaceutical industry, as they have the potential to reshape the standard of care for patients. The landscape of hemophilia B treatment is continually shifting, with numerous companies diligently pursuing the development of novel therapies that could bring transformative changes to how we treat hemophilia B.<\/p>\n\n\n\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26163314\/Hemophilia-B-Market-Share-Segmentation-of-the-7MM-2032.webp\" alt=\"Hemophilia B Market Share (%) Segmentation of the 7MM (2032)\" class=\"wp-image-25418\" width=\"449\" height=\"143\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26163314\/Hemophilia-B-Market-Share-Segmentation-of-the-7MM-2032.webp 599w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26163314\/Hemophilia-B-Market-Share-Segmentation-of-the-7MM-2032-300x96.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26163314\/Hemophilia-B-Market-Share-Segmentation-of-the-7MM-2032-150x48.webp 150w\" sizes=\"(max-width: 449px) 100vw, 449px\" \/><\/figure>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\">\n<p><em>As per DelveInsight analysis, by 2025, the total <\/em><a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-market\"><em>market size of hemophilia B AAV gene therapies<\/em><\/a><em> in the 7MM is estimated to be approximately <\/em><strong><em>~300 USD million<\/em><\/strong><em>. The current standard of care treatment for severe hemophilia B is the prophylactic intravenous replacement of coagulation factor IX (FIX) to prevent spontaneous bleeding.<\/em><\/p>\n<\/blockquote>\n\n\n\n<p>Currently, HEMGENIX holds the exclusive approval as an AAV gene therapy for hemophilia B. Nevertheless, a new contender, fidanacogene elaparvovec, is gaining momentum in the development hemophilia B pipeline. Both treatments function by delivering a functional variant of the mutated factor IX gene, intensifying the rivalry between these two therapies, each vying to rectify the fundamental genetic defect and provide a cure for hemophilia B.<\/p>\n\n\n\n<p>In conclusion, the future of gene therapies for <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-market\">hemophilia B treatment<\/a> holds great promise, offering the potential for a paradigm shift in treatment approaches. As gene therapy continues to advance, addressing challenges and refining techniques, it has the potential to significantly improve the lives of individuals living with hemophilia B. While there is still much work to be done, the journey towards more effective and accessible treatment options is well underway.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large is-resized\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-market\"><img decoding=\"async\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161702\/Hemophilia-B-Market-Outlook-1024x256.webp\" alt=\"Hemophilia B Market Outlook\" class=\"wp-image-25414\" width=\"768\" height=\"192\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161702\/Hemophilia-B-Market-Outlook-1024x256.webp 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161702\/Hemophilia-B-Market-Outlook-300x75.webp 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161702\/Hemophilia-B-Market-Outlook-150x38.webp 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161702\/Hemophilia-B-Market-Outlook-768x192.webp 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161702\/Hemophilia-B-Market-Outlook-1536x384.webp 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161702\/Hemophilia-B-Market-Outlook-1568x392.webp 1568w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161702\/Hemophilia-B-Market-Outlook.webp 1584w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Hemophilia B is a rare genetic bleeding disorder in which affected individuals have insufficient levels of a blood protein called factor IX. Around 3 in 100 individuals with hemophilia B produce an antibody to the factor IX replacement therapy used to treat or avoid their bleeding episodes, called an inhibitor. The inhibitor prevents the therapy [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":25411,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[16988,21396,257,20666,285,21395,21394],"industry":[17225],"therapeutic_areas":[17238,17233],"class_list":["post-25410","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-aav-gene-therapies","tag-aav-gene-therapies-for-hemophilia-b-treatment","tag-gene-therapies","tag-hemgenix","tag-hemophilia-b","tag-hemophilia-b-market","tag-hemophilia-b-treatment","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-hematological-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Emerging AAV Gene Therapies for Hemophilia B Treatment<\/title>\n<meta name=\"description\" content=\"Future of gene therapies for hemophilia B treatment holds great promise, offering the potential for a paradigm shift in treatment approaches.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Emerging AAV Gene Therapies for Hemophilia B Treatment\" \/>\n<meta property=\"og:description\" content=\"Future of gene therapies for hemophilia B treatment holds great promise, offering the potential for a paradigm shift in treatment approaches.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-27T13:17:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-01-05T05:29:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161517\/aav-gene-therapies-for-hemophilia-b-treatment.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Emerging AAV Gene Therapies for Hemophilia B Treatment","description":"Future of gene therapies for hemophilia B treatment holds great promise, offering the potential for a paradigm shift in treatment approaches.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment","og_locale":"en_US","og_type":"article","og_title":"Emerging AAV Gene Therapies for Hemophilia B Treatment","og_description":"Future of gene therapies for hemophilia B treatment holds great promise, offering the potential for a paradigm shift in treatment approaches.","og_url":"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-10-27T13:17:36+00:00","article_modified_time":"2024-01-05T05:29:01+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161517\/aav-gene-therapies-for-hemophilia-b-treatment.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment","url":"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment","name":"Emerging AAV Gene Therapies for Hemophilia B Treatment","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161517\/aav-gene-therapies-for-hemophilia-b-treatment.webp","datePublished":"2023-10-27T13:17:36+00:00","dateModified":"2024-01-05T05:29:01+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Future of gene therapies for hemophilia B treatment holds great promise, offering the potential for a paradigm shift in treatment approaches.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/aav-gene-therapies-for-hemophilia-b-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161517\/aav-gene-therapies-for-hemophilia-b-treatment.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161517\/aav-gene-therapies-for-hemophilia-b-treatment.webp","width":772,"height":482,"caption":"aav-gene-therapies-for-hemophilia-b-treatment"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/10\/26161517\/aav-gene-therapies-for-hemophilia-b-treatment-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AAV Gene therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AAV Gene Therapies for Hemophilia B Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Gene Therapies<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">HEMGENIX<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">hemophilia B<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hemophilia B Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Hemophilia B Treatment<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AAV Gene therapies<\/span>","<span class=\"advgb-post-tax-term\">AAV Gene Therapies for Hemophilia B Treatment<\/span>","<span class=\"advgb-post-tax-term\">Gene Therapies<\/span>","<span class=\"advgb-post-tax-term\">HEMGENIX<\/span>","<span class=\"advgb-post-tax-term\">hemophilia B<\/span>","<span class=\"advgb-post-tax-term\">Hemophilia B Market<\/span>","<span class=\"advgb-post-tax-term\">Hemophilia B Treatment<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Oct 27, 2023","modified":"Updated on Jan 5, 2024"},"absolute_dates_time":{"created":"Posted on Oct 27, 2023 6:47 pm","modified":"Updated on Jan 5, 2024 10:59 am"},"featured_img_caption":"aav-gene-therapies-for-hemophilia-b-treatment","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=25410"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25410\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/25411"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=25410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=25410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=25410"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=25410"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=25410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}